Journal
LEUKEMIA RESEARCH
Volume 27, Issue 2, Pages 133-145Publisher
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/S0145-2126(02)00085-1
Keywords
mevalonate pathway; statin; ras; chemosensitizing; isoprenylation
Categories
Funding
- NCI NIH HHS [K12-CA76930, CA18029, UO1-CA32102] Funding Source: Medline
- NIDDK NIH HHS [DK38432, DK54200] Funding Source: Medline
Ask authors/readers for more resources
The 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase is a rate-limiting enzyme in the mevalonate biochemical pathway and HMG-CoA reductase inhibitors (statins) show toxicity for certain tumors, including acute myeloid leukemia (AML). This toxicity has been attributed to statin inhibition of Ras isoprenylation in tumors like AML where oncogenic ras mutations and/or overexpression are common. We show that mevastatin kills certain AML cell lines and is more toxic to a majority of primary AML cell samples than to myeloid cells in bone marrow (BM) samples from normal donors, and that mevastatin can produce more than additive kill with standard chemotherapeutics. Mevastatin reduces Ras membrane localization, but statin sensitivity in primary AML cells is not consistently associated with ras mutations nor with Ras overexpression, suggesting that another mevalonate pathway by-products) is the statin target in at least some AMLs. (C) 2002 Elsevier Science Ltd. All fights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available